Similar articles for PMID: 20810517

Year	Number of Results
2003	1
2004	3
2005	1
2006	4
2007	1
2008	1
2009	3
2010	4
2011	3
2012	9
2013	8
2014	3
2015	6
2016	12
2017	12
2018	6
2019	7
2020	10
2021	6
2022	2
2024	0

1

Assessing changes in relapse rates in multiple sclerosis.

Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, Cutter GR. Inusah S, et al. Mult Scler. 2010 Dec;16(12):1414-21. doi: 10.1177/1352458510379246. Epub 2010 Sep 1. Mult Scler. 2010. PMID: 20810517 Review.

2

Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.

Nicholas R, Straube S, Schmidli H, Schneider S, Friede T. Nicholas R, et al. Mult Scler. 2011 Oct;17(10):1211-7. doi: 10.1177/1352458511406309. Epub 2011 May 17. Mult Scler. 2011. PMID: 21586489 Review.

3

Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.

Steinvorth SM, Röver C, Schneider S, Nicholas R, Straube S, Friede T. Steinvorth SM, et al. Mult Scler. 2013 Oct;19(12):1580-6. doi: 10.1177/1352458513481009. Epub 2013 Mar 7. Mult Scler. 2013. PMID: 23471144 Free article. Review.

4

Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis.

Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T. Nicholas R, et al. Mult Scler. 2012 Sep;18(9):1290-6. doi: 10.1177/1352458511435715. Epub 2012 Mar 15. Mult Scler. 2012. PMID: 22422808 Review.

5

Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.

Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA. Roskell NS, et al. Curr Med Res Opin. 2012 May;28(5):767-80. doi: 10.1185/03007995.2012.681637. Epub 2012 Apr 24. Curr Med Res Opin. 2012. PMID: 22462530

6

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L. He D, et al. Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3. Cochrane Database Syst Rev. 2016. PMID: 27003123 Free PMC article. Review.

7

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Goldberg LD, et al. J Manag Care Pharm. 2009 Sep;15(7):543-55. doi: 10.18553/jmcp.2009.15.7.543. J Manag Care Pharm. 2009. PMID: 19739877 Free PMC article.

8

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.

Stellmann JP, Neuhaus A, Herich L, Schippling S, Roeckel M, Daumer M, Martin R, Heesen C. Stellmann JP, et al. PLoS One. 2012;7(11):e50347. doi: 10.1371/journal.pone.0050347. Epub 2012 Nov 29. PLoS One. 2012. PMID: 23209717 Free PMC article.

9

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H. He D, et al. Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Cochrane Database Syst Rev. 2013. PMID: 24310855 Review.

10

Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.

Poncet-Megemont L, Pereira B, Rollot F, Sormani MP, Clavelou P, Moisset X. Poncet-Megemont L, et al. Mult Scler. 2022 Aug;28(9):1457-1466. doi: 10.1177/13524585211052400. Epub 2021 Oct 26. Mult Scler. 2022. PMID: 34697961

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

93 results

Results by year